Paolo Tarantino: True honour to have the opportunity of joining the outstanding faculty of JSMO24 to review

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Erika Hamilton on X/Twitter, adding:

“True honour to have the opportunity of joining the outstanding faculty of JSMO24 to review the many exciting targeted agents in development to better treat our patients with hormone receptor positive metastatic breast cancer.”

Quoting Erika Hamilton’s post:

“Paolo Tarantino discusses the future of molecular targeted drugs in bcsm at JSMO24. PIK3CA most commonly mutated in endometrial and bcsm CDK after CDK benefit still a bit unclear in bcsm but more data is emerging.”

Source: Paolo Tarantino/X and Erika Hamilton/X

Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective. Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.